Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Jurczak W, et al. Among authors: maddocks k. Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056. Ann Oncol. 2018. PMID: 29444231 Free PMC article. Clinical Trial.
Ibrutinib in B-cell Lymphomas.
Maddocks K, Blum KA. Maddocks K, et al. Curr Treat Options Oncol. 2014 Jun;15(2):226-37. doi: 10.1007/s11864-014-0274-8. Curr Treat Options Oncol. 2014. PMID: 24481980 Review.
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA. Cohen JB, et al. Cancer. 2014 Jun 1;120(11):1677-85. doi: 10.1002/cncr.28642. Epub 2014 Feb 27. Cancer. 2014. PMID: 24578014 Free PMC article.
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA. Maddocks K, et al. Am J Hematol. 2015 Apr;90(4):327-33. doi: 10.1002/ajh.23946. Epub 2015 Feb 25. Am J Hematol. 2015. PMID: 25639448 Free PMC article. Clinical Trial.
Treatment strategies in mantle cell lymphoma.
Maddocks K, Blum KA. Maddocks K, et al. Cancer Treat Res. 2015;165:251-70. doi: 10.1007/978-3-319-13150-4_10. Cancer Treat Res. 2015. PMID: 25655613 Review.
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. Christian BA, et al. Among authors: maddocks k. Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7. Br J Haematol. 2015. PMID: 25847298 Free PMC article. Clinical Trial.
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Liu TM, et al. Among authors: maddocks k. Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13. Blood. 2015. PMID: 25972157 Free PMC article.
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Jaglowski SM, et al. Among authors: maddocks kj. Blood. 2015 Aug 13;126(7):842-50. doi: 10.1182/blood-2014-12-617522. Epub 2015 Jun 26. Blood. 2015. PMID: 26116658 Free PMC article. Clinical Trial.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Maddocks KJ, et al. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. JAMA Oncol. 2015. PMID: 26182309 Free PMC article.
133 results